ARCA biopharma Stock Price, News & Analysis (NASDAQ:ABIO)

$1.45 0.00 (0.00 %)
(As of 11/17/2017 08:00 AM ET)
Previous Close$1.45
Today's Range$1.35 - $1.55
52-Week Range$1.05 - $3.00
Volume250,726 shs
Average Volume87,943 shs
Market Capitalization$17.04 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81

About ARCA biopharma (NASDAQ:ABIO)

ARCA biopharma logoARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.


Industry, Sector and Symbol:
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Sector: Biopharmaceuticals
  • Symbol: NASDAQ:ABIO
  • CUSIP: N/A
  • Web: arcabio.com
Debt:
  • Current Ratio: 6.44%
  • Quick Ratio: 6.44%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $1.22 per share
  • Price / Book: 1.19
Profitability:
  • Trailing EPS: ($1.92)
  • Net Income: ($16,440,000.00)
  • Return on Equity: -106.97%
  • Return on Assets: -93.36%
Misc:
  • Employees: 20
  • Outstanding Shares: 11,750,000
 

Frequently Asked Questions for ARCA biopharma (NASDAQ:ABIO)

What is ARCA biopharma's stock symbol?

ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO."

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) issued its quarterly earnings data on Thursday, November, 9th. The biopharmaceutical company reported ($0.39) EPS for the quarter. View ARCA biopharma's Earnings History.

Who are some of ARCA biopharma's key competitors?

Who are ARCA biopharma's key executives?

ARCA biopharma's management team includes the folowing people:

  • Robert E. Conway, Chairman of the Board (Age 62)
  • Michael R. Bristow M.D., Ph.D., President, Chief Executive Officer, Director (Age 71)
  • Thomas A. Keuer, Chief Operating Officer (Age 56)
  • Christopher David Ozeroff, Senior Vice President, General Counsel, Secretary (Age 57)
  • Brian L. Selby CPA, Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance (Age 53)
  • Linda S. Grais M.D., Lead Independent Director (Age 61)
  • Anders D. Hove M.D., Director (Age 50)
  • Daniel J. Mitchell, Director (Age 58)
  • Raymond L. Woosley M.D., Ph.D., Director (Age 72)

Who owns ARCA biopharma stock?

ARCA biopharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Royce & Associates LP (2.00%). Company insiders that own ARCA biopharma stock include Brian L Selby, Christopher David Ozeroff, Daniel J Mitchell, Michael R Bristow, Robert E Conway and Thomas A Keuer. View Institutional Ownership Trends for ARCA biopharma.

Who bought ARCA biopharma stock? Who is buying ARCA biopharma stock?

ARCA biopharma's stock was purchased by a variety of institutional investors in the last quarter, including Royce & Associates LP. Company insiders that have bought ARCA biopharma stock in the last two years include Daniel J Mitchell and Robert E Conway. View Insider Buying and Selling for ARCA biopharma.

How do I buy ARCA biopharma stock?

Shares of ARCA biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ARCA biopharma's stock price today?

One share of ARCA biopharma stock can currently be purchased for approximately $1.45.

How big of a company is ARCA biopharma?

ARCA biopharma has a market capitalization of $17.04 million. The biopharmaceutical company earns ($16,440,000.00) in net income (profit) each year or ($1.92) on an earnings per share basis. ARCA biopharma employs 20 workers across the globe.

How can I contact ARCA biopharma?

ARCA biopharma's mailing address is 11080 Circle Point Rd Ste 140, WESTMINSTER, CO 80020-2769, United States. The biopharmaceutical company can be reached via phone at +1-720-9402200 or via email at [email protected]


MarketBeat Community Rating for ARCA biopharma (NASDAQ ABIO)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  27 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  72
MarketBeat's community ratings are surveys of what our community members think about ARCA biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for ARCA biopharma (NASDAQ:ABIO)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for ARCA biopharma (NASDAQ:ABIO)

Price Target History for ARCA biopharma (NASDAQ:ABIO)

Analysts' Ratings History for ARCA biopharma (NASDAQ:ABIO)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/23/2016Royal Bank Of CanadaReiterated RatingSector Perform$5.00 -> $4.00N/AView Rating Details
2/23/2016Cowen and CompanyReiterated RatingMarket Perform$5.50 -> $4.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for ARCA biopharma (NASDAQ:ABIO)

Earnings by Quarter for ARCA biopharma (NASDAQ:ABIO)

Earnings History by Quarter for ARCA biopharma (NASDAQ ABIO)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.39)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.59)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.48)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.51)ViewN/AView Earnings Details
8/9/2016Q216($0.43)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ARCA biopharma (NASDAQ:ABIO)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for ARCA biopharma (NASDAQ:ABIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ARCA biopharma (NASDAQ ABIO)

Insider Ownership Percentage: 3.75%
Institutional Ownership Percentage: 39.07%
Insider Trades by Quarter for ARCA biopharma (NASDAQ:ABIO)
Institutional Ownership by Quarter for ARCA biopharma (NASDAQ:ABIO)

Insider Trades by Quarter for ARCA biopharma (NASDAQ ABIO)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/14/2017Robert E ConwayChairmanBuy10,000$2.49$24,900.00View SEC Filing  
5/2/2017Daniel J MitchellDirectorBuy11,000$2.71$29,810.00View SEC Filing  
4/4/2017Christopher David OzeroffVPSell418$2.41$1,007.38View SEC Filing  
4/4/2017Michael R. BristowInsiderSell720$2.41$1,735.20View SEC Filing  
4/4/2017Thomas A. KeuerCOOSell390$2.41$939.90View SEC Filing  
4/3/2017Brian L. SelbyVPSell1,114$2.46$2,740.44View SEC Filing  
3/24/2017Robert E ConwayDirectorBuy25,000$2.59$64,750.00View SEC Filing  
2/28/2017Michael R. BristowInsiderSell763$2.61$1,991.43View SEC Filing  
2/28/2017Thomas A. KeuerCOOSell465$2.61$1,213.65View SEC Filing  
10/18/2016Thomas A. KeuerCOOSell483$2.45$1,183.35View SEC Filing  
9/20/2016Christopher David OzeroffVPSell1,185$2.89$3,424.65View SEC Filing  
9/20/2016Michael R. BristowInsiderSell1,972$2.89$5,699.08View SEC Filing  
9/20/2016Thomas A. KeuerCOOSell714$2.89$2,063.46View SEC Filing  
9/19/2016Brian L. SelbyVPSell476$2.91$1,385.16View SEC Filing  
4/5/2016Christopher David OzeroffVPSell366$3.52$1,288.32View SEC Filing  
4/5/2016Michael R BristowInsiderSell724$3.52$2,548.48View SEC Filing  
4/5/2016Thomas A KeuerCOOSell384$3.52$1,351.68View SEC Filing  
4/4/2016Brian L SelbyVPSell1,114$3.52$3,921.28View SEC Filing  
3/1/2016Christopher David OzeroffVPSell458$3.51$1,607.58View SEC Filing  
3/1/2016Michael R. BristowInsiderSell752$3.50$2,632.00View SEC Filing  
3/1/2016Thomas A. KeuerCOOSell457$3.53$1,613.21View SEC Filing  
9/18/2015Christopher David OzeroffVPSell1,129$6.32$7,135.28View SEC Filing  
3/2/2015Brian L SelbyVPSell1,125$0.71$798.75View SEC Filing  
3/2/2015Michael R BristowInsiderSell5,446$0.71$3,866.66View SEC Filing  
1/16/2015Riley MccormackMajor ShareholderSell350,000$0.76$266,000.00View SEC Filing  
1/7/2015Riley MccormackMajor ShareholderSell550,000$0.92$506,000.00View SEC Filing  
9/18/2014Michael R BristowCEOSell13,853$1.30$18,008.90View SEC Filing  
9/18/2014Patrick M WheelerCFOSell8,246$1.31$10,802.26View SEC Filing  
2/4/2014Riley MccormackMajor ShareholderBuy1,000,000$1.70$1,700,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ARCA biopharma (NASDAQ:ABIO)

Latest Headlines for ARCA biopharma (NASDAQ ABIO)

Source:
DateHeadline
Colorado biotech shares soars after patent issued in EuropeColorado biotech shares soars after patent issued in Europe
www.bizjournals.com - November 16 at 10:36 AM
ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic TargetingARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting
finance.yahoo.com - November 16 at 10:36 AM
ARCA biopharma, Inc. (ABIO) Announces  Earnings ResultsARCA biopharma, Inc. (ABIO) Announces Earnings Results
www.americanbankingnews.com - November 10 at 12:51 PM
ARCA biopharma, Inc. (ABIO) Announces  Earnings ResultsARCA biopharma, Inc. (ABIO) Announces Earnings Results
www.americanbankingnews.com - November 10 at 12:51 PM
ARCA biopharma Announces Third Quarter 2017 Financial Results and Provides Business UpdateARCA biopharma Announces Third Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - November 9 at 4:17 PM
ARCA biopharma, Inc. (ABIO) to Release Quarterly Earnings on MondayARCA biopharma, Inc. (ABIO) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - November 6 at 5:20 AM
ARCA biopharma Inc (ABIO): How Does It Impact Your Portfolio?ARCA biopharma Inc (ABIO): How Does It Impact Your Portfolio?
finance.yahoo.com - October 23 at 8:22 PM
ARCA biopharma (ABIO) Presents At The Sidoti & Company Fall 2017 Convention - SlideshowARCA biopharma (ABIO) Presents At The Sidoti & Company Fall 2017 Convention - Slideshow
seekingalpha.com - September 29 at 3:05 PM
ARCA biopharma to Present at the Sidoti & Company Fall 2017 ConferenceARCA biopharma to Present at the Sidoti & Company Fall 2017 Conference
finance.yahoo.com - September 21 at 3:30 PM
Arca Biopharma (ABIO) Reports Completion of Enrollment for GENETIC-AF Phase 2B Clinical TrialArca Biopharma (ABIO) Reports Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial
www.streetinsider.com - August 16 at 8:23 PM
ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical TrialARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial
finance.yahoo.com - August 16 at 3:21 PM
GLPGs FLORA Blooms, DVAX, ESPR Price Offering, SGMO Abuzz, HRTX On TrackGLPG's FLORA Blooms, DVAX, ESPR Price Offering, SGMO Abuzz, HRTX On Track
www.rttnews.com - August 10 at 9:48 PM
BRIEF-ARCA Biopharma to share top-line results in Q1 next year for GENETIC-AF trialBRIEF-ARCA Biopharma to share top-line results in Q1 next year for GENETIC-AF trial
www.reuters.com - August 10 at 1:24 AM
ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim AnalysisARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis
finance.yahoo.com - August 9 at 8:23 PM
ARCA biopharma, Inc. (NASDAQ:ABIO) Issues Quarterly  Earnings ResultsARCA biopharma, Inc. (NASDAQ:ABIO) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 5 at 12:56 PM
ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business UpdateARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 3 at 8:37 PM
ARCA biopharma, Inc. (NASDAQ:ABIO) Scheduled to Post Earnings on MondayARCA biopharma, Inc. (NASDAQ:ABIO) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - July 31 at 8:01 AM
ARCA biopharma, Inc. (ABIO) Chairman Buys $24,900.00 in StockARCA biopharma, Inc. (ABIO) Chairman Buys $24,900.00 in Stock
www.americanbankingnews.com - July 17 at 7:36 PM
BRIEF-ARCA Biopharma Q1 loss per share $0.48BRIEF-ARCA Biopharma Q1 loss per share $0.48
www.reuters.com - May 15 at 3:15 PM
BRIEF-Arca Biopharma Inc files for mixed shelf of up to $75 mlnBRIEF-Arca Biopharma Inc files for mixed shelf of up to $75 mln
www.businessinsider.com - April 27 at 1:26 AM
FDA Nod For Parkinsons Drug, ABIO Awaits Data In Q3, Busy Year Ahead For VKTXFDA Nod For Parkinson's Drug, ABIO Awaits Data In Q3, Busy Year Ahead For VKTX
www.rttnews.com - March 22 at 3:17 PM
ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business UpdateARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update
www.businesswire.com - March 21 at 8:22 PM
NOVN Moves Ahead, PTCT Finally Achieves It, TGTX Gets GENUINE ReactionNOVN Moves Ahead, PTCT Finally Achieves It, TGTX Gets GENUINE Reaction
www.rttnews.com - March 7 at 3:15 PM
ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal OfficersARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 1 at 8:16 PM
Anders Hove, M.D. (Photo: Business Wire)Anders Hove, M.D. (Photo: Business Wire)
www.thestreet.com - February 21 at 3:32 PM
ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitsARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - February 21 at 3:32 PM
ARCA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitARCA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit
biz.yahoo.com - January 11 at 8:17 PM
ARCA biopharma Announces Third Quarter 2016 Financial Results and Provides Business UpdateARCA biopharma Announces Third Quarter 2016 Financial Results and Provides Business Update
www.businesswire.com - November 14 at 8:55 PM
BRIEF-Arca Biopharma Q3 loss per share $0.51BRIEF-Arca Biopharma Q3 loss per share $0.51
www.reuters.com - November 14 at 8:55 PM
Dr. Michael R. Bristow, President And CEO, ARCA Biopharma, Inc.Dr. Michael R. Bristow, President And CEO, ARCA Biopharma, Inc.
www.thestreet.com - October 7 at 8:02 AM
EARS Faces The Music, ABIO On Track, TEVA Gets EU Nod For Asthma DrugEARS Faces The Music, ABIO On Track, TEVA Gets EU Nod For Asthma Drug
www.rttnews.com - August 19 at 11:29 AM
BRIEF-Arca says 100th patient randomized into the genetic-AF phase 2b/3 clinical trialBRIEF-Arca says 100th patient randomized into the genetic-AF phase 2b/3 clinical trial
www.reuters.com - August 18 at 3:15 PM
Form 4 ARCA biopharma, Inc. For: Jun 09 Filed by: Selby Brian L.Form 4 ARCA biopharma, Inc. For: Jun 09 Filed by: Selby Brian L.
www.streetinsider.com - June 15 at 3:16 PM
ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote oARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote o
biz.yahoo.com - June 13 at 5:01 PM
ARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update - Business Wire (press release)ARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update - Business Wire (press release)
www.businesswire.com - May 12 at 9:47 AM
ARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly ReportARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - May 11 at 4:49 PM
ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - April 18 at 4:31 PM
ARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial - Business Wire (press release)ARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial - Business Wire (press release)
www.businesswire.com - April 18 at 10:27 AM
ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhiARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
biz.yahoo.com - March 17 at 4:44 PM

Social Media

Financials

Chart

ARCA biopharma (NASDAQ ABIO) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.